The Establishment and Maintenance of a Comprehensive Thoracic Tumor Data Registry and Bioreceptor 
Aims: The purpose of this database is to allow researchers to review and compare medical information including medical history, symptoms, medical test results, treatments and complications that people with thoracic tumor may have. Another purpose of this study is to collect leftover tissue obtained during thoracic surgery or diagnostic tests. Research testing of this tissue may help to determine the changes which lead to the development and/or spread of cancer. This information may help to develop new kinds of diagnostic tests and treatment for thoracic cancer.
Diagnosis: Thoracic Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH98-136
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact research coordinator Ujala Bokary at 847.570.1783
Open to Enrollment: Yes

S1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Aims: The purpose of this study screening step is to perform genetic tests on your tumor sample for certain features that investigational targeted agents used in this study are specifically designed to work against. Then the purpose is to assign you to a treatment sub-study that is chosen based on the results (genes and proteins called "biomarkers") of this genetic testing on your tumor sample. This study related "research test" will be done in a special lab. The system of assigning a treatment sub-study based on genetic testing of cancer is investigational; in squamous cell lung cancer patients, we don’t know whether testing can identify patients who will or will not benefit from treatment. The purpose of the treatment part of this study is to compare the effects, good and bad, of these investigational agents to the usual approach to treating your type of cancer. It may be possible that you will not be able to participate in the treatment part of this study. This could happen if it is unsafe for you to receive the investigational treatment. You may also choose to not participate in the treatment portion of the study. Before you decide to get treatment on the study, you will be given information about the study treatment and you will be asked if you wish to continue on this research study.
Diagnosis: Squamous Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH14-415
Sponsor: Southwest Oncology Group
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

S1507: A Phase II Trial of Trametinib with Docetaxel in Patients with KRAS Mutation Positive, Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Aims: The study is testing the effects of the combination of trametinib and docetaxel in cancer that has recurred after other treatments.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH17-129
Sponsor: Southwest Oncology Group
Contact: For more information, interested participants may contact Michele Britto, RN at 847-570-2109
Open to Enrollment: Yes

E4512: Testing the Addition of Drug Crizotinib After Surgery to Remove ALK-Positive Non-Small Cell Lung Cancer: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Aims: The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI(R)), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer. In addition of crizotinib may help prevent your cancer from returning, but it could also cause side effects. This research study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Ki Wan Kim, MD
IRB Approval Number: EH15-121
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Claudia Fredian, RN at 847.570.1512
Open to Enrollment: Yes

A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Aims: The purpose of this research study is to determine if patietns iwth Non-Small Cell Lung Cancer (NSCLC) have a mutation (abnormal change) in the DNA or their tumor and if so, which one.  The genetic mutations which are being assessed are: EGFR, ALK, an dPD-L1.  Not all lung tumors have the changes in genes.  The study will lead into two optional treatment trials which will use specific drugs to target these genes as well as tumors without mutations.  Tissue from the tumor removed at the time of surgery is sent to a national laboratory to be analyzed and compared to local results. 
Diagnosis: Non-Small Cell Lung Cancer (NSCLC) Stage IB, II, IIIA
Principal Investigator: Ki Wan Kim, MD
IRB Approval Number: EH15-122
Sponsor: Alliance
Contact: Interested patients should contact research nurse Claudia Fredian, RN at 847.570.1512
Open to Enrollment: Yes

A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Aims: The purpose of this research study is to compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (and investigational drug).
Diagnosis: Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator: Ki Wan Kim, MD 
IRB Approval Number: EH15-123
Sponsor: Alliance
Contact: Interested patients should contact research nurse Claudia Fredian, RN at 847.570.1512
Open to Enrollment: Yes

Mirati 0103-020: a Phase 1 / 2 Study of HDAC Inhibitor, Mocetinostat, in Combination with PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer
Aims: The purpose of this research study is to see whether the combination of Mocetinostat and Durvalumab , both investigational drugs given together, will be effetive in treating patients with non-small cell lung cancer
Diagnosis: Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH16-309
Sponsor: Mirati Therapeutics, Inc.
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

Best Practive in VATS Lobectomy and Segmentectomy for Lung Cancer: A Prospective, Observational, Quality Improvement Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS)
Aims: This is a multi-center study which will be conducted at seven sites. The purpose of this study is to establish a database for doing data and cost analysis of the workup, early treatment and follow-up of patients who have VATS lobectomy or segmentectomy for lung cancer.
Diagnosis: Lung Cancer
Principal Investigator: Seth Krantz, MD
IRB Approval Number: EH13-155
Sponsor: Ethicon Endo Surgery
Contact: Interested participants may contact Ujala Bokhary, MBBS, CCRP at 847.570.1783, ubokhary@northshore.org
Open to Enrollment
: Yes

Mirati: 265-109: Phase 2, Parallel-Arm Study of GCD265 in Patients wtih Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Facto
Aims: The purpose of this study is to see if you have the changes in tumor genes that are targeted by this drug, MGCD265. If you have the changes, then you will be given this drug and we will be assessing side effecte, efficacy and how this drug is absorbed and eliminated from the body.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH16-105
Sponsor: Mirati Therapeutics
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to enrollment: Yes

AFT-09: Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition with Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients with Chemotherapy naive stage IV Non-Small Cell Lung Cancer
Aims: The purpose of this study is to see  the administration of standard platinum-based chemotherapy before pembrolizumab (immune therapy) would improve response rates compared to pembrolizumab alone before chemotherapy.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH16-169
Sponsor: Mirati Therapeutics
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to enrollment: Yes

EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Aims:
The purpose of this research study is to find out whether treatment with nivolumab (also known as OPDIVO), a type of immunotherapy will result in improved survival over placebo for patients with STage IB-IIIA NSCLC following complete resection and standard post-operative therapy.  This study is the treatment trial linked to A151216 Alchemist trial withere the tissue is sent for  determiniation of gene mutations post operatively.
Diagnosis: Non-Small Cell Lung Cancer (NSCLC) Stages IB, II, IIIA
Principal Investigator: Ki Wan Kim, MD
IRB Approval Number: EH16-268
Sponsor: Alliance
Contact: Interested patients should contact research nurse Claudia Fredian, RN at 847.570.1512, cfredia
Open to Enrollment: Yes